Just a bit of dreaming here as we wait for top line results or perhaps an SSRA at 188 adjudicated events.

One of my hopes is that we would see more regional licensing agreements signed as the trial gets closer to completion. I was thinking that there could be risk management strategies like CVR type deals for the rights to distribute and market apabetalone in some of the EU countries, South Africa, India, Pakistan, Russia and some South American countries.

My (unrealized) hope is that, as Don has stated, there are a number of LOIs and that perhaps one or more might be regional rights deals that would, unlike Medison in Israel, bring some cash into the coffers as the trial approaches completion.

Wishful thinking but perhaps if a successful SSRA is completed it could trigger a regional deal or 2 pre top lines.

In the meantime the usual business such as attending seminars to get the word out there seems to be flowing along well and this is a very big improvement from where we were just a couple of months ago in May 2018.

The FDA's NDA letter, the possibility of a NASDAQ listing and the independent research on new indications are the types of signs that reinforce my confidence in this science.

I don't expect the conferences to bear any tangible fruit but they are a necessary condition of business. In terms of the AGM my expectation is that the big news will be approval of the concept of a reverse split. I don't expect any other big news at that meeting but I'll hope for a positive update with perhaps new information.

GLTA

Toinv